Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders

Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders

US Patent 11559588 · Granted Jan 24, 2023

Estimated economic value: $56,580,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Materials and methods for treatment of pain related disorders2025
Materials and methods for treatment of pain related disorders2025
Materials and methods for treatment of pain related disorders2025
Materials and methods for treatment of pain related disorders2025
Methods and systems to quantify and index correlation risk in financial markets 2025
Materials and methods for treatment of hereditary haemochromatosis2025
CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and use2024
Materials and methods for treatment of Duchenne Muscular Dystrophy2024
Materials and methods for treatment of hemoglobinopathies2024
Methods and systems to extract signals from large and imperfect datasets2024
Compositions and methods for gene editing2024
Compositions and methods for gene editing2024